Cancer Institute A national cancer institute
designated cancer center

Ronald Levy, MD

Publication Details

  • Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors BLOOD Brody, J. D., Goldstein, M. J., Czerwinski, D. K., Levy, R. 2009; 113 (1): 85-94

    Abstract:

    Ex vivo-expanded tumor-infiltrating lymphocytes infused into lymphodepleted recipients has clear antitumor efficacy. More practical sources of such antitumor lymphocytes would broaden the application of this approach. Previously, we described an in situ vaccination combining chemotherapy with intratumoral injection of CpG-enriched oligonucleotides, which induced T-cell immunity against established lymphoma. An ongoing clinical trial of this maneuver has demonstrated clinical responses in lymphoma patients. Here, we use this vaccine maneuver to generate immune cells for transfer into irradiated, syngeneic recipients. Transferred tumor-specific T-effector (T(eff)) cells preferentially expanded, increasing the T(eff)/T-regulatory (T(reg)) ratio in these "immunotransplantation" recipients and curing large and metastatic tumors. Donor T cells were necessary for tumor protection, and CD8 T-cell immune responses were enhanced by posttransplantation booster vaccination. Hematopoietic stem cell transplantation is a standard therapy for lymphoma. Therefore, in situ tumor vaccination followed by immunotransplantation of harvested tumor-specific T cells could be directly tested in clinical trials to treat otherwise resistant malignancies.

    View details for DOI 10.1182/blood-2008-05-155457

    View details for Web of Science ID 000262162800015

    View details for PubMedID 18812472

Stanford Medicine Resources:

Footer Links: